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Abstract
This study investigated the presence of cell membrane docking proteins synaptosomal-associated protein, 25 and 23 kD (SNAP-25 and SNAP-
23) in satellite glial cells (SGCs) of rat trigeminal ganglion; whether cultured SGCs would release glutamate in a time- and calcium-dependent
manner following calcium-ionophore ionomycin stimulation; and if botulinum neurotoxin type A (BoNTA), in a dose-dependent manner, could
block or decrease vesicular release of glutamate. SGCs were isolated from the trigeminal ganglia (TG) of adult Wistar rats and cultured for
7 days. The presence of SNAPs in TG sections and isolated SGCs were investigated using immunohistochemistry and immunocytochemistry,
respectively. SGCs were stimulated with ionomycin (5 lM for 4, 8, 12 and 30 min.) to release glutamate. SGCs were then pre-incubated with
BoNTA (24 hrs with 0.1, 1, 10 and 100 pM) to investigate if BoNTA could potentially block ionomycin-stimulated glutamate release. Glutamate
concentrations were measured by ELISA. SNAP-25 and SNAP-23 were present in SGCs in TG sections and in cultured SGCs. Ionomycin signifi-
cantly increased glutamate release from cultured SGCs 30 min. following the treatment (P < 0.001). BoNTA (100 pM) significantly decreased
glutamate release (P < 0.01). Results from this study demonstrated that SGCs, when stimulated with ionomycin, released glutamate that was
inhibited by BoNTA, possibly through cleavage of SNAP-25 and/or SNAP-23. These novel findings demonstrate the existence of vesicular gluta-
mate release from SGCs, which could potentially play a role in the trigeminal sensory transmission. In addition, interaction of BoNTA with non-
neuronal cells at the level of TG suggests a potential analgesic mechanism of action of BoNTA.
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Introduction
The trigeminovascular system, which consists of neurons, blood ves-
sels and non-neuronal cells (glial cells), is an important player in cra-
niofacial nociception [1, 2]. Dysfunction of this system is considered
a potential mechanism underlying the development and/or mainte-
nance of painful conditions such as migraine headaches [3]. Trigemi-
nal ganglia (TG) contain the cell bodies of pseudo-unipolar neurons,
which are surrounded by non-neuronal satellite glial cells (SGCs).
Neuron-glia interaction within the sensory ganglia is based on this
unique functional structure [4], where only an average distance of
20 nm exists between SGCs and their associated neurons allowing
exchange of chemicals between the two cell types [5]. Neuron-glia
interaction under physiological conditions is crucial for optimal func-
tioning [6], and it is gradually becoming evident that under pathologi-
cal pain conditions, this interaction is disturbed [7, 8].
One of the substances proposed to contribute to neuron-glia
cross talk is excitatory amino acid glutamate, and disruption of gluta-
mate metabolism by SGCs could lead to increased level of glutamate
within the TG [9, 10]. We have recently demonstrated that trigeminal
SGCs in rats contain glutamate and express excitatory amino acid
transporters (EAAT) and that the cultured SGCs can be stimulated
with potassium chloride (10 mM) to release glutamate [11]. We also
demonstrated that intraganglionic injection of glutamate in vivo
evoked afferent discharges, which were increased by the EAAT1 and
EAAT2 blocker, (3S)-3-[[3-[[4-(trifluoromethyl)benzoyl]amino]phe-
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nyl]methoxy]-L-aspartic acid. Elevated levels of glutamate within the
TG also lowered the mechanical threshold of the masticatory muscle
afferent fibres; an effect that was attenuated by the N-methyl-D-aspar-
tate receptor antagonist, 2-amino-5-phosphonovalerate [11]. How-
ever, this study did not determine whether SGCs can release
glutamate through calcium-dependent vesicular process.
Vesicular release of glutamate occurs through binding of the vesi-
cle to the cell membrane SNARE docking complexes that contain the
synaptosomal-associated protein of 25 kD (SNAP-25) and/or its ana-
logue, SNAP-23 [12, 13]. Signalling between astrocytes and neurons
via glutamate has been extensively studied [12, 14]. Under experi-
mental conditions, calcium-dependent release of glutamate can be
stimulated by different agents such as bradykinin and calcium-iono-
phore, ionomycin [14, 15]. Botulinum neurotoxin type A (BoNTA) is
known to inhibit vesicular release of glutamate (and other neurotrans-
mitters) by cleaving neuronal SNAP-25 [16–18]. BoNTA has been
shown to inhibit glutamate release by non-neuronal cells of the cen-
tral nervous system, such as astrocytes and microglia [13, 14]; but, it
is unclear if peripheral glia, SGCs, would also express SNAPs and
respond to BoNTA in the same way as the central glia.
Hence, the present study was designed to investigate (i) qualita-
tive presence of SNAP-25 and SNAP-23 in trigeminal SGCs; (ii)
whether the cultured trigeminal SGCs would release glutamate in a
time- and calcium-dependent manner following stimulation by iono-
mycin; and (iii) if BoNTA would block or decrease the vesicular
release of glutamate from these cells. Results from this study would
not only shed light on possible role(s) of peripheral non-neuronal
cells (SGCs) in trigeminal sensory transmission, but also advance our
understanding about mechanism(s) of analgesic action of BoNTA at
the level of sensory ganglia.
Materials and methods
Animals
The study was performed with 20 adult male Wistar rats (2–4 months
old) provided through the Animal Research Facility, Department of
Pathology, Aalborg University Hospital, Denmark. Animals were housed
in groups of three rats per cage, in temperature-controlled rooms, on a
12 hrs light/dark cycle with access to food and water ad libitum. All ani-
mals were deeply anesthetized and then killed prior to all experimental
procedures. All procedures were conducted according to ethical guide-
lines defined by the Danish Animal Experiments Inspectorate in accor-
dance with the guidelines set by the International Association for the
Study of Pain for use of laboratory animals in medical research.
Immunohistochemistry
Animals were deeply anesthetized with a mixture of hypnorm
(Vm21757/4000; Vetapharma, Leeds, West Yorkshire, UK), midazolam
(Hameln Pharmaceuticals, Gloucester, UK), and isotonic saline (25%,
25%, 50% v/v. 0.3 ml/100 g) prior to transcardial perfusion with iso-
tonic saline followed by 10% formalin buffer solution (BAF-0010-03A;
CellPath, Newtown, Wales, UK). The TG were removed and placed in
10% formalin buffer solution overnight at 4°C. The next day the ganglia
were washed in PBS (14190-094; Gibco Life Technologies, Invitrogen,
CA, Waltham, USA) and placed in 20% sucrose solution for 48 hrs at
4°C. The tissue was then placed in 40% sucrose solution overnight at
4°C for cryoprotection. Afterwards, the ganglia were embedded in Tis-
sue-Tek (4583; Sakura Finetek, Alphen aan den Rijn, The Netherlands)
and frozen separately in a cryo-mould (4565; Sakura Finetek). Ganglia
were sectioned with a cryostat (MICROM; Thermo Fisher Scientific,
Waltham, Germany; 10 lm). Sections were mounted on poly-L-lysine
coated glass slides (1510.1260; Hounisen Laboratorieudstyr, Glostrup,
Denmark) and incubated in 5% bovine serum albumin (BSA; EQBAH62;
Europa Bioproducts, Cambridge, UK) supplemented with 0.2% Triton
X100 for 1 hr at room temperature (RT) before they were washed with
PBS. Primary antibodies against glutamine synthetase (GS: G2781;
Sigma-Aldrich, St. Louis, MO, USA; 1:10,000; rabbit), and either SNAP-
23 (ab166808; Abcam, Cambridge, UK; 1:100; goat) or SNAP-25
(ab136493; Abcam; 1:100; goat) in 1% BSA solution were added and
incubated at 4°C overnight. Slides were washed in PBS and incubated
with secondary antibody Donkey anti-rabbit Alexa Fluor 555 conjugate
1:500 (ab150074; Abcam) and Donkey anti-goat Alexa Fluor 488 conju-
gate 1:500 (ab150129; Abcam), in 1% BSA, for 1 hr at RT. The nuclear
dye Hoechst was added for 10 min. at RT, in a 1:2000 dilution in 1%
BSA, before the slides were washed in PBS and milli-Q water. Subse-
quently, the slides were mounted with glass cover slips (Fluorescent
mounting medium; S3023; Dako, Denmark) and images were obtained
using a Nikon microscope (Az100; Nikon, Tokyo, Japan) equipped with
a fluorescent illuminator (L200/D; Prior Scientific, Rockland, MA, USA)
and a digital camera (DS-Vi1; Nikon) connected to a personal computer.
Image J (public domain software) was used for further analysis.
Primary trigeminal ganglion cell cultures
Animals were deeply anesthetized with a mixture of hypnorm
(Vm21757/4000; Vetapharma), midazolam (Hameln Pharmaceuticals),
and isotonic saline (25%, 25%, 50% v/v. 0.3 ml/100 g) and killed by
cervical dislocation. The TG were removed, cut into smaller sections
with microscissors, placed in 5 mg/ml collagenase suspension (C9891;
Sigma-Aldrich) in Ham’s F12 growth medium (21765-029; Gibco Life
Technologies, Invitrogen) supplemented with 1% penicillin/streptomycin
(15140; Gibco Life Technologies, Invitrogen) and incubated (37°C) for
15 min. Following incubation, the collagenase solution was centrifuged
(280 g) for 5 min. The pellet was re-suspended in 1 ml 0.125% trypsin
(15090-046; Gibco Life Technologies, Invitrogen) and placed in the
incubator for 5–10 min. prior centrifugation (5 min./280 g). The sec-
tioned and enzymatically digested ganglia were then mechanically disso-
ciated into a homogenous solution by repeated pipetting. The cell
solution was added to uncoated culture flasks before being placed in an
incubator (37°C – 95% air/ 5% CO2). The growth medium was changed
after 3 and 24 hrs, and then continuously every 2–3 days prior to the
experimental procedure.
Immunocytochemistry
Cells were washed with PBS prior to fixation in 10% formalin buffer
solution (BAF-0010-03A; CellPath) for 15–20 min. Afterwards, 0.2% Tri-
ton X-100 (X100; Sigma-Aldrich) was added for 15 min. The cells were
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washed twice in PBS before incubated in 5% BSA for 1 hr at RT. Pri-
mary antibodies against GS (G2781; Sigma-Aldrich; 1:4000; rabbit), and
either SNAP-23 (ab166808; Abcam; 1:200; goat) or SNAP-25
(ab136493; Abcam; 1:200; goat) were diluted in 1% BSA solution and
incubated overnight at 4°C. The following day, cells were washed prior
to incubation with secondary antibodies donkey anti-rabbit Alexa Fluor
555 conjugate 1:500 (ab150074; Abcam) and donkey anti-goat Alexa
Fluor 488 conjugate 1:500 (ab150129; Abcam), in a 1% BSA solution,
for 1.5 hrs in the dark. Subsequently, the cells were incubated with Hoe-
chst for 10 min. at 4°C, in a concentration of 1:2000. Afterwards, the
cells were washed in PBS and then milli-Q water before mounted with
glass cover slips (Fluorescent mounting medium; S3023; Dako). Images
were obtained using a Nikon microscope (Az100; Nikon) equipped with a
fluorescent illuminator (L200/D; Prior Scientific) and a digital camera
(DS-Vi1; Nikon) connected to a personal computer. Image J (public
domain software) was used for further analysis.
Glutamate release evoked by ionomycin
Once cell confluence attained 90%, the supplemented growth medium
was washed off and replaced with the glutamate-free DMEM
(A1515401; Invitrogen) and left in the incubator overnight. The DMEM
was replaced by fresh DMEM for control or treatment medium consist-
ing of 5 lM ionomycin (I3909; Sigma-Aldrich) in DMEM. The concen-
tration of ionomycin was chosen based on a previous work [15].
Samples were collected from control and treatment culture medium
after 4, 8, 12, and 30 min. The time-points were selected based on the
previous work showing a quick release of glutamate within minutes fol-
lowing treatment with ionomycin [15]. Cytotoxic potential of ionomycin
(in terms of concentration and time of exposure) has already been
reported,* where ionomycin at high concentration (100 lM) produces
pronounced morphological changes after only 4 hrs. Maximal cell death
at high concentration occurs within 10–20 hrs after the treatment.
Although the cells tested in the past were from a different origin, it
seems unlikely that the time and concentration of ionomycin selected
for this study would cause any cytotoxic effect on trigeminal SGCs.
The glutamate concentrations in the collected samples were deter-
mined using a competitive immunoassay for quantitative determination
of glutamate in biological samples (BA E-2300; Labor Diagnostika Nord,
Nordhorn, Germany).
Effect of BoNTA on ionomycin-evoked glutamate
release from cultured SGCs
Once cell confluence attained 90%, the supplemented growth medium
was washed off and replaced with the glutamate-free DMEM (A1515401;
Invitrogen) and left in the incubator overnight. The DMEM was aspirated
and replaced with pre-treatment medium containing 0.1, 1, 10 and
100 pM of BoNTA (Botox, Allegan, CA, USA) in DMEM or with DMEM
alone, and placed in the incubator (37°C) for 24 hrs. The calculations
from Units to pM were done following the information obtained from the
producer; each of the 200 U vials of Botox represents 9.6 ng of 900 kD
toxin. Each vial was then dissolved in 0.1 ml of medium. A total of 20
vials were used to reach a stock solution of 100 pM. The subsequent
concentrations were reached with serial dilutions of the stock solution.
The concentrations of BoNTA and pre-treatment timing were chosen
based on the previous publications [19, 20]. It has also been reported that
1.6 and 3.1 units of BoNTA are within the therapeutic concentrations,
which have been used to study direct inhibitory effect of BoNTA on release
of calcitonin gene-related peptide in primary cultures of rat TG [21].
After 24 hrs, pre-treatment medium was replaced by 0.75% dimethyl
sulfoxide in DMEM (control), or a mixture of 50 lM BAPTA (1,2-bis(o-
aminophenoxy)ethane-N,N,N0,N0-tetraacetic acid; A4926; Sigma-Aldrich),
which selectively chelates intracellular calcium that is essential for gluta-
mate release used here as a positive control, plus 5 lM ionomycin in
DMEM, or 5 lM ionomycin alone in DMEM. The concentration of BAPTA
was chosen based on a previous work [22]. Samples of the cultured
medium were collected after 30 min. of incubation. Glutamate concen-
trations in the collected samples were determined using a competitive
immunoassay for quantitative determination of glutamate in biological
samples (BA E-2300; Labor Diagnostika Nord).
Statistical analysis
The effects of BoNTA on ionomycin-evoked glutamate release were
analysed with repeated measures ANOVA (RM ANOVA; repeated factor:
time). For the remaining data, one-way ANOVA was used. The Bonfer-
roni test was used for post hoc comparison. All statistical tests were
carried out by IBM (Armonk, New York, US). SPSS, version 20. Data
are presented as mean  SEM. P < 0.05 was considered statistically
significant.
Results
Localization of SNAP-25 and SNAP-23 in
trigeminal SGCs
Fluorescence microscopy was used to identify the expression of
SNAP-25 and SNAP-23 in SGCs. The SGCs were characterized by
double labelling with GS, a specific marker for SGCs in the periph-
eral ganglia. Figures 1 and 2 show, respectively, the immunoreac-
tivity of SNAP-25 and SNAP-23 and how they were distributed.
Double labelling between SNAP-25 or SNAP-23 and GS was used
to identify positive SGCs for SNAP in cryostat tissue sections of
the TG. SNAP-25 and SNAP-23 were also present and observed in
cultured cells as presented in Figures 3 and 4, respectively.
Glutamate release evoked by ionomycin
The time-dependent stimulatory effect of ionomycin on glutamate
release was investigated in the cultured SGCs. Samples were obtained
at 4, 8, 12 and 30 min. after treatment with ionomycin and control.
*Worzella T, Niles A, Helley L, Conley M and Riss T. An Image-Based
Method for Real-Time Monitoring of Cytotoxicity Using CellToxTM Green
Dye and the Essen Bioscience IncuCyteTM FLR Live Content Imaging Sys-
tem. Promega Corporation: http://www.promega.com/resources/pubhub/
monitoring-cytotoxicity-using-celltox-green-and-the-incucyte-live-content-
imagingsystem/Updated October 2013.
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Ionomycin increased glutamate levels at 30 min., when compared to
control (P < 0.01). No significant difference was detected between
control and the first three time-points (4, 8 and 12 min.) after iono-
mycin treatment (Fig. 5).
Modulatory effect of BoNTA on ionomycin-evoked
release of glutamate from cultured SGCs
The modulatory effect of BoNTA on glutamate release from SGCs was
investigated (Fig. 6). Stimulation with ionomycin significantly
increased the glutamate concentration compared with control
(P < 0.001). Pre-treatment with 100 pM BoNTA was able to signifi-
cantly decrease the glutamate concentration when compared to iono-
mycin alone (P < 0.01) or a lower concentration of BoNTA (10 pM,
P < 0.05). No significant difference was detected for pre-treatment
with 0.1, 1 or 10 pM of BoNTA when compared to ionomycin alone
(P > 0.05). BAPTA significantly decreased glutamate concentration
when compared with ionomycin alone (P < 0.05).
Discussion
This study demonstrated that: (i) The cell membrane docking proteins
SNAP-25 and SNAP-23 are expressed by trigeminal SGCs; (ii)
cultured SGCs, when stimulated with ionomycin, release glutamate
and (iii) BoNTA inhibited the release of glutamate from SGCs possibly
through cleavage of SNAP-25 and/or SNAP-23, which would inhibit
vesicular docking.
Presence of SNAP-25 and SNAP-23 in trigeminal
SGCs
The SNARE (soluble N-ethylmaleimide sensitive factor attachment pro-
tein receptor) complex comprises a large group of membrane-associ-
ated proteins that enables transmitter vesicle docking and its fusion to
the cell membrane. The vesicles in response to calcium influx undergo
rapid exocytotic fusion and release neurotransmitters such as gluta-
mate [23, 24]. SNAP-25 is one of the proteins from the SNARE com-
plex, and it is well-known that BoNTA cleaves SNAP-25 and blocks the
release of transmitters that are stored in vesicles [18, 25]. Murine
SNAP-23 is also cleaved by BoNTA [26]. SNAP-23 is an SNAP-25 ana-
logue protein found in non-neuronal cells [13]. In amino acid composi-
tion, SNAP-23 is 59% identical to SNAP-25 [27]. In non-neuronal cells,
SNAP-23 performs similar functions in vesicle docking and fusion to
membrane for transmitter release [27, 28]. BoNTA is also known to
cleave SNAPs in non-neuronal cells of the central nervous system,
such as astrocytes and microglia [13, 14]. Although it has been shown
that SNAP-25 is present in cell bodies of neurons isolated from TG [4],
A B
C D
Fig. 1 Localization of SNAP-25 in trigemi-
nal satellite glial cells in rat. The blue col-
our represents the nuclear stain Hoechst,
which stains the nuclei of each cell (A).
SNAP-25 positive satellite glial cells were
identified by double labelling with antibod-
ies against glutamine synthetase, a spe-
cific satellite glial cell marker in ganglia
(Red: Alexa fluor 555) (B) and SNAP-25
(Green: Alexa fluor 488) (C). On the
merged image (D) overlapping of the two
colours indicates SNAP-25 positive SGCs.
The enhanced area on image (D) shows
an example of such co-localization of
satellite glial cells enveloping a neuron.
4 ª 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
the present study show that both SNAP-25 and SNAP-23 are present
in trigeminal SGCs. Interestingly, cultured SGCs maintained the in vivo
expression of SNAPs. It has been reported that SNAP-25 has been
detected at highest level within the first few days after astrocytes cul-
turing, whereas prolonged culture time reduced SNAP-25 dramatically
[29]; however, several studies from astrocytes and microglia could
only detect SNAP-23 [13, 30]. Verderio et al. reported the presence of
SNAP-23 in Schwann cells [31]. Recently, Marinelli et al. have
provided direct evidence that SNAP-25 is present in astrocytes. In
addition, this group has provided direct evidence that cl-SNAP25 is
co-localized with GFAP in rat sciatic nerve sections. Considering that
GFAP is expressed in non-myelinating cells as well as proliferating
Schwann cells, this finding may indirectly demonstrate that BoNTA
cleaves SNAP-25 in Schwann cells [32]. Further investigations may
provide direct evidence; whether inhibitory effect of BoNTA on SGCs as
it was seen in our study is a result of interaction with SNAP-25, or
SNAP-23 or another unknown mechanism(s). Expression of SNAP-23
or SNAP-25 in glial cells indicates that these cells are capable of cal-
cium-dependent vesicular release of substances, which can be modu-
lated by agents capable of blocking the vesicular release. Trigeminal
SGCs contain glutamate, and release it under certain condition such as
inflammation or injury [5]. This process, if involved in trigeminal noci-
ception, could potentially be modulated to help developing better strat-
egies for treating craniofacial pain conditions.
Ionomycin-evoked glutamate release
Glutamate is an excitatory neurotransmitter, which plays an essential
role in peripheral nociception [33, 34]. It has been shown that gluta-
mate is one of the key molecules in craniofacial pain conditions
including migraine [35]. Several preclinical studies have also investi-
gated the role of glutamate in association with nociception and mus-
cle sensitization in rats and in humans [36, 37].
Using pharmacological tools, such as KCl, bafilomycin and
ionomycin, to elicit glutamate release is commonly used in both
neurons and non-neuronal cells. We have recently demonstrated
that trigeminal SGCs in rat contain glutamate, express EAAT1 and
EAAT2, and, under conditions of elevated potassium concentra-
tion, release glutamate through EAATs [11]. Here we addressed
whether glutamate can be released from trigeminal SGCs by cal-
cium-dependent vesicular exocytosis through the use of the iono-
phore ionomycin. Ionomycin, has also been used to provoke
glutamate release from Schwann cells [15] and central glia, astro-
cytes [14], at a similar concentration as applied in this study
(5 lM).
Our data provide evidence of vesicular release of glutamate by
trigeminal SGCs occurs, which can potentially affect TG neurons and
neighbouring SGCs that express glutamate receptors [11, 38, 39].
These findings suggest that glutamatergic transmission within TG
A B
C D
Fig. 2 Localization of SNAP-23 in trigemi-
nal satellite glial cells in rat. The blue col-
our on image (A) represents the nuclear
stain Hoechst and stains the nuclei of
each cell. SNAP23 positive satellite glial
cells were identified by double labelling
with antibodies against glutamine synthe-
tase (Red: Alexa fluor 555), a specific
Satellite glial cell marker in ganglia (B)
and SNAP-23 (Green: Alexa fluor 488)
(C). On the merged image (D) overlapping
of the two colours indicates SNAP23 posi-
tive SGCs. The enhanced area on image
(D) shows an example of such co-localiza-
tion of satellite glial cells enveloping a
neuron.
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could impact nociception and neuron-glia cross talk [10]. In addition,
as it is shown here and elsewhere [40], that cultured SGCs are capa-
ble of maintaining some of their functionality for stimulation and
release of substances, such as glutamate in culture and hence in vitro
studies can provide a platform suitable for investigating responsive-
ness of SGCs to a given compound under different treatment condi-
tions [40].
Mechanisms of glutamate release from astrocytes have already
been studied extensively and it has been reported that astrocytes
release glutamate that can influence the activity of their neighbour-
ing neurons through six different mechanisms [41], one of those is
calcium-dependent exocytosis. However, it is not yet known which
pathways and the extent to which each mechanism contributes to
the release of glutamate by astrocytes. It is also unclear if similar
or different glutamate release mechanisms occur under physiologi-
cal and pathophysiological conditions. Given the general consider-
ation that SGCs function in the peripheral nervous system is closer
to central astrocytes, compared with other types of glial cells [7], it
can be postulated that similar mechanisms for glutamate release
from SGCs could eventually exist. The calcium-dependent glutamate
release from astrocytes suggests exocytosis as a possible mecha-
nism, which utilizes SNARE complex for vesicle fusion [42–44].
Both SNAP-23 and SNAP-25 have been found in astrocytes [30];
the present study confirmed the existence of SNAP-23 and
SNAP-25 in SGCs both in vivo and in vitro. Isoforms of vesicular
glutamate transporters 1, 2 and 3, have also been detected in as-
trocytes and play a functional role in mediating calcium-dependent
glutamate release from astrocytes. We have also found vesicular
glutamate transporters 1 and 2 in trigeminal SGCs and have stud-
ied functional role of these transporters in glutamate release [11].
Our present data advanced understanding of biological role(s) of
SNAPs expression on SGCs and calcium-dependent glutamate
release from these cells.
BoNTA reduced ionomycin-evoked glutamate
release from SGCs
Consistent with our recent investigations towards elucidating poten-
tial roles of SGCs in craniofacial nociception [11, 38, 40], we
addressed here the open question of vesicular release of glutamate
by trigeminal SGCs and proposed that if these cells contain gluta-
mate, and release it under specific conditions, what could be a
potential mechanism(s). Our results demonstrated that BoNTA
reduced glutamate release from trigeminal SGCs, where its effect
was concentration-dependent. Although still under further investiga-
tion in our lab and by others, based on several in vivo and in vitro
experiments, it is assumed that antinociceptive mechanism of BoN-
TA is because of cleavage of SNAP-25, one of the SNARE proteins
essential for neurotransmitter release [16, 45]. This protein is
A B
C D
Fig. 3 Immunocytochemistry of 7-day-old
primary cultures of satellite glial cells
from rat trigeminal ganglia. Image (A),
shows the nuclei of the satellite glial cell
stained with the nuclear stain Hoechst.
The cultures are double labelled with anti-
bodies against glutamine synthetase (Red:
Alexa fluor 555) (B) and SNAP-25
(Green: Alexa fluor 488) (C). The merged
image (D) is an overlay of all channels
and this image shows the co-localization
of glutamine synthetase and SNAP-25 in
cultured rat trigeminal satellite glial cells.
Virtually all SGCs seem SNAP-25 positive.
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located on the cell membrane of neurons and its deactivation is
calcium-dependent and prevents the release of several known neu-
rotransmitters contributing in nociception e.g. glutamate, Calcitonin
gene-related peptide (CGRP), and Substance P (SP) [21, 46, 47].
Since we demonstrated here that trigeminal SGCs express SNAPs,
both 25 and 23, in vivo and in vitro, we proposed that the inhibi-
tory effect of BoNTA on ionomycin-evoked glutamate release seen
in the preset study is because of the cleavage of SNAPs by the
toxin [26].
It has been proposed that BoNTA can be transported to sen-
sory ganglia and block the release of substances involved in pain
transmission from the ganglion neurons [48, 49]. Recently, a group
of researchers have demonstrated the presence of the cleaved
SNAP-25 in dorsal root ganglia after BoNTA injection in the periph-
ery [32]. This group has also reported that, in the spinal cord,
BoNTA may be transcytosed from nociceptive fibres and enter into
astrocytes, as shown by the detection of cleaved SNAP-25 in astro-
cytes. However, the functional consequences of such observations
remain largely unknown and require further investigation. For
instance, it is still not known whether BoNTA molecule or cleaved
SNAP-25 can reach to the TG through this retrograde transport
after intramuscular injection into the craniofacial muscles, and if it
is so, what would be the consequences on SGCs enveloping
A B
C D
Fig. 4 Immunocytochemistry of 7-day-old
primary cultures of satellite glial cells
from rat trigeminal ganglia. Image (A),
shows the nuclei of the satellite glial cell
stained with the nuclear stain Hoechst.
The cultures are double labelled with anti-
bodies against glutamine synthetase (Red:
Alexa fluor 555) (B) and SNAP-23
(Green: Alexa fluor 488) (C). The merged
image (D) is an overlay of all channels
and this image shows the co-localization
of glutamine synthetase and SNAP-23 in
cultured rat trigeminal satellite glial cells.
Virtually all SGCs seem SNAP-23 positive.
Fig. 5 Time-dependent modulation of glutamate release by ionomycin.
Glutamate concentration (lM) in culture medium after 4, 8, 12 and
30 min. of 5 lM ionomycin incubation. **P < 0.01 indicates the signifi-
cant difference of glutamate release when ionomycin is compared with
control at 30 min.; #P < 0.05 indicates that glutamate release at 30 min
is different compared with other stimulation time-points. Results are
shown as mean  SEM.
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the somata of the trigeminal neurons. Further morphological and
experimental studies are required to extensively evaluate the poten-
tial migration and effects of BoNTA in sensory ganglia following its
peripheral administration. This will assist a better understanding
of the toxin effects in the peripheral nervous system following
treatments for inflammatory or neuropathic pain conditions.
Investigating the effect of BoNTA in sensory ganglia must also
address potential safety issues.
It is known that BoNTA recognizes and enters neurons by
binding to the synaptic vesicle protein SV2 [50] but other iso-
forms in cultured astrocytes [51]. Whether the same process
occurs when BoNTA gets in contact with SGCs is not known.
The assumption is that as vesicle fusion is mediated by a set of
SNARE proteins and the light chain of BoNTA exerts a proteolytic
function to cleave specific peptide bonds present in the synaptic
fusion complex, it can prevent exocytosis of neurotransmitter
containing vesicles similar to what has been shown at nerve ter-
minals [50, 52]. Inhibition of glutamate release from SGCs,
shown in this study, emphasizes the potential role of peripheral
non-neuronal cells in nociceptive signalling at the level of sen-
sory ganglia.
Our study is not an exemption from limitations and we recognize
the value and importance of quantitative information on expression of
the SNAPs in trigeminal SGCs. Further investigation to provide this
information and also to examine the extent of SNAPs that undergoes
cleavage by BoNTA is warranted. Such information might assist in
better describing the antinociceptive/analgesic effects of BoNTA at
the level of sensory ganglia. Currently, it is less obvious whether the
main form of SNAP in SGCs is SNAP-23 or SNAP-25, nor it is deter-
mined yet that under which conditions BoNTA cleaves different
SNAPs. For example, Vaidyanathan et al. [26], demonstrated that
BoNTA cleaves murine SNAP-23; however, only at high concentration
and after a long incubation time. It is difficult to speculate if our pres-
ent experiments have achieved similar cleavages as Vaidyanathan
et al. (3.6%) especially considering the different glial cell types, use
of complete form of the toxin instead of L-chain and also different
incubation timing. It also needs to be clarified whether SGCs, under
different age stage and conditions, would respond differently to
BoNTA.
There might be an effect of ‘all or nothing’ in response to the
toxin. We have presented a dose–response result in this study;
however, it has been shown that for example, at 3 U/kg, BoNTA
seems not to affect the carrageenan- and capsaicin-evoked pain,
but at slightly higher dose (3.5 U/kg), it does. Interestingly, increas-
ing the dose to 5 and 7 U/kg, BoNTA exerts similar analgesic activ-
ity [53]. Similar antinociceptive effect of 3.5, 7 and 15 U/kg BoNTA
doses was reported in a formalin test [47]. Increased analgesic
effects have been shown to occur at higher doses of the applied
toxin (20–40 U/kg) but animal motor performance is affected in
high doses and most likely interfere with the sensory responsive-
ness [47, 54]. Consistent with basic research results, it seems that
clinical trials have not addressed a clear dose–response of BoNTA
and the employed doses are mainly based on the clinical effects
[55]. These observations might be proven for the effect of BoNTA
on glial cells. There might be a lowest potential dose of BoNTA in
which the SGCs respond and further increase would potentially not
add any additional increase in responsiveness. We are not able to
fully clarify this point with the current results, but as we have
observed that the inhibitory effect of BoNTA on glutamate release
occurred between 10 and 100 pM, it would be useful to see what
would be the lowest effective concentration of BoNTA between 10
and 100 pM.
Conclusions
Results from this study demonstrated that SNAP-25 and SNAP-23
are present in trigeminal SGCs. It was also demonstrated that SGCs,
when stimulated with ionomycin, release glutamate, which is inhibited
by BoNTA. This study also shed lights into analgesic action of BoNTA
at the level of sensory ganglia, with an emphasis on the role of
peripheral non-neuronal cells.
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